# OnCo record paper-heo-cancerdetect-validation-plos-one-2025 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-heo-cancerdetect-validation-plos-one-2025/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-heo-cancerdetect-validation-plos-one-2025" ;
  schema:name "Analytical validation of a hybrid-approach combining tumor-informed and tumor-agnostic bespoke ctDNA panel assay for the sensitive detection of minimal residual disease"@en ;
  schema:description "The laboratory validation of IMBdx's personalised blood test for leftover cancer, which reached one part in 100,000 on test mixtures."@en ;
  schema:url <https://onco.cc/key-papers/paper-heo-cancerdetect-validation-plos-one-2025/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://doi.org/10.1371/journal.pone.0334282>, <https://pubmed.ncbi.nlm.nih.gov/41212866/> ;
  schema:sameAs <https://doi.org/10.1371/journal.pone.0334282> ;
  schema:datePublished "2025"^^xsd:gYear ;
  schema:author "Heo S, Ham SK, Lee H, et al." ;
  onco:sections <https://onco.cc/fronts/diagnostics/> ;
  onco:technologies <https://onco.cc/technologies/mrd-testing/> ;
  onco:drugs <https://onco.cc/drugs/cancerdetect-imbdx/> ;
  onco:companies <https://onco.cc/companies/imbdx/> ;
  onco:terms <https://onco.cc/terms/mrd/>, <https://onco.cc/terms/ctdna/>, <https://onco.cc/terms/tumour-informed-assay/> .